Microvesicle-associated tissue factor and Trousseau's syndrome

被引:79
作者
Del Conde, I.
Bharwani, L. D.
Dietzen, D. J.
Pendurthi, U.
Thiagarajan, P.
Lopez, J. A.
机构
[1] Univ Washington, Sch Med, Puget Sound Blood Ctr, Seattle, WA 98104 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[4] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
[5] Univ Texas Hlth Ctr, Biomed Res Ctr, Tyler, TX USA
[6] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[7] Michael E DeBakey VA Med Ctr, Dept Pathol, Houston, TX USA
[8] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX USA
关键词
cancer; microvesicles; thrombosis; tissue factor; Trousseau's syndrome;
D O I
10.1111/j.1538-7836.2006.02301.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Trousseau's syndrome is a prothrombotic state associated with malignancy that is poorly understood pathophysiologically. Methods and Results: Here we report studies on the blood of a 55-year-old man with giant-cell lung carcinoma who developed a severe form of Trousseau's syndrome. His clinical course was dominated by an extremely hypercoagulable state. Despite receiving potent antithrombotic therapy, he suffered eleven major arterial and venous thrombotic events over a 5 month period. We examined the patient's blood for tissue factor (TF), the major initiator of coagulation, and found its concentration in his plasma to be forty-one-fold higher than the mean concentration derived from testing of 16 normal individuals. Conclusion: Almost all of the TF in the patient's plasma was associated with cell-derived microvesicles, likely shed by the cancer cells.
引用
收藏
页码:70 / 74
页数:5
相关论文
共 27 条
[1]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]   INITIATION OF COAGULATION BY TISSUE FACTOR [J].
BACH, RR .
CRC CRITICAL REVIEWS IN BIOCHEMISTRY, 1988, 23 (04) :339-368
[3]   TROUSSEAUS SYNDROME - DEVASTATING COAGULOPATHY IN THE ABSENCE OF HEPARIN [J].
BELL, WR ;
STARKSEN, NF ;
TONG, S ;
PORTERFIELD, JK .
AMERICAN JOURNAL OF MEDICINE, 1985, 79 (04) :423-430
[4]   Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein [J].
Bogdanov, VY ;
Balasubramanian, V ;
Hathcock, J ;
Vele, O ;
Lieb, M ;
Nemerson, Y .
NATURE MEDICINE, 2003, 9 (04) :458-462
[5]  
CALLANDER N, 1993, WESTERN J MED, V158, P364
[6]   Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation [J].
del Conde, I ;
Shrimpton, CN ;
Thiagarajan, P ;
López, JA .
BLOOD, 2005, 106 (05) :1604-1611
[7]  
Dietzen DJ, 2003, THROMB HAEMOSTASIS, V89, P65
[8]  
DONATI MB, 1994, HAEMOSTASIS, V24, P128
[9]  
DRAKE TA, 1989, AM J PATHOL, V134, P1087
[10]   TUMOR SHEDDING AND COAGULATION [J].
DVORAK, HF ;
QUAY, SC ;
ORENSTEIN, NS ;
DVORAK, AM ;
HAHN, P ;
BITZER, AM ;
CARVALHO, AC .
SCIENCE, 1981, 212 (4497) :923-924